Business Context and Reporting Period
This Form 8-K Current Report covers events for Revelation Biosciences, Inc. (REVB) with a report date of January 17, 2025, and a signature date of January 21, 2025. The filing primarily details the results of a Special Meeting of Stockholders held on January 17, 2025, and the commencement of a new clinical study.
Key Financial Metrics
This filing is a current report regarding corporate governance and operational events; it does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The filing notes that as of the record date for the Special Meeting, there were 6,464,219 shares of common stock issued and outstanding entitled to vote.
Material Changes and Voting Results
Stockholders voted on four proposals at the Special Meeting. The results were as follows:
- Proposal 1 (Reverse Stock Split): Approved. Stockholders granted the Board discretionary authority to effect a reverse stock split at a ratio between 1-for-2 and 1-for-50 within one year. Votes: 3,955,277 For; 162,665 Against; 21,665 Abstain.
- Proposal 2 (Change of Domicile): Failed. The proposal to move the company's domicile from Delaware to Nevada did not receive the required number of affirmative votes from outstanding shares, despite 97% of voting stockholders present supporting it. Votes: 2,956,575 For; 73,597 Against; 20,134 Abstain. There were 1,089,301 broker non-votes.
- Proposal 3 (Warrant Issuance Cap): Approved. Stockholders approved the issuance of shares pursuant to Class F and Class G Warrants (dated December 3, 2024) even if issuances exceed 20% of total outstanding shares, potentially triggering the Nasdaq Rule 5635(d) cap. Votes: 2,370,106 For; 410,665 Against; 269,535 Abstain.
- Proposal 4 (Adjournment Authority): Approved. Stockholders approved the Board's authority to adjourn the meeting if insufficient proxies were present to approve the reverse stock split. Votes: 3,947,430 For; 181,210 Against; 10,967 Abstain.
Outlook, Risks, and Operational Updates
Clinical Development: On January 21, 2025, the Company announced the start of its PRIME Phase 1b Clinical Study of its drug candidate, Gemini, in patients with Chronic Kidney Disease (CKD).
Corporate Structure Risks: The failure of the Change of Domicile proposal means the Company remains incorporated in Delaware. The approval of the Reverse Stock Split provides the Board flexibility to adjust share count to maintain compliance with Nasdaq listing standards, though the specific ratio has not yet been set.
Warrant Inducement: The approval of Proposal 3 facilitates a warrant inducement transaction, allowing for potential dilution beyond the standard 20% Nasdaq cap, subject to the specific terms of the warrants issued in December 2024.
Investor Verification Checklist
- Verify the specific reverse stock split ratio and effective date once determined by the Board of Directors.
- Monitor the Company's share price and trading volume to assess compliance with Nasdaq minimum bid price requirements following the potential reverse split.
- Review the terms of the Class F and Class G Warrants issued on December 3, 2024, to understand potential dilution impacts.
- Track the progress and preliminary data of the PRIME Phase 1b Clinical Study for Gemini in CKD patients.
- Confirm the Company's cash runway and liquidity position in subsequent filings (e.g., 10-Q or 10-K), as this 8-K does not contain financial statements.